N/A N=112 Coronavirus Disease of 2019 (COVID-19) Health Education Initiative for School Safety
COVID-19
Primary: Evaluation of Acceptability of Intervention as Measured by Acceptability Questionnaire — 4.47 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=245 Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments
Covid19 · Sars-CoV-2 Infection
Primary: SARS-CoV-2 Infection — 4; 2 Participants
N/A N=4,142 COVID-19: Human Epidemiology and Response to SARS-CoV-2
Coronavirus Disease 2019 (COVID-19) · SARS-CoV-2
Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…
N/A N=1,102 Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic
COVID-19
Primary: Number and Severity of Confirmed COVID-19 Infections Among Cancer Centre Staff and Patients at 12 Months — 55; 36 Participants
Phase 1 N=18 This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)
SARS-CoV-2 Infection
Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants
N/A N=7,444 Mental and Physical Well-Being of Frontline Health Care Workers During Coronavirus Disease 2019 (COVID-19)
Healthy
Primary: PTSD Symptom Severity — 16.36; 17.10; 15.56; 15.78 score on a scale — p=.77
N/A N=3,632 Epidemiological Study of the COVID-2019 in Participating Organizations.
Covid19
Primary: The Incidence of COVID-2019 Cases. — 259.95 COVID-2019 cases per 1000 person
N/A N=69 Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19
Covid19
Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants
N/A N=2,097 COVID-19 Watch + COVID-19 Pulse
Covid19
Primary: Difference in Days Alive and Out of Hospital — 29.5; 29.4 days
N/A N=2,598 HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
HIV-1-infection · COVID-19
Primary: Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of…
Phase 4 N=44 Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)
Diarrhea · COVID-19
Primary: Measure of Daily Stool Frequency for Patients With COVID Treated With Bismuth — 3 bowel movements
N/A N=2,778 You and Me COVID Free
COVID-19
Primary: Main Reason for Testing for COVID-19 — 1632; 493; 238; 343 Participants
Phase 2 N=5 Treat COVID-19 Patients With Regadenoson
COVID-19 · Lung Inflammation
Primary: Proportion of Patients Alive and Free of Respiratory Failure Through the 30-day Trial. — 100 Percentage of of patients alive and free
N/A N=118 Study to Evaluate Efficacy and Safety of "VIRACIDE" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)
Covid19
Primary: Number of Participants With National Early Warning Score (NEWS) Change From 3 to 0 — 44; 29 Participants
Phase 3 N=220 A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
COVID-19
Primary: Proportion of Patients Without Any Need for INV Until EoS — 98; 101; 12; 9 Participants
N/A N=270 The Impact of the COVID-19 (SARS-CoV-2 Disease) on Psychopathology
Psychosis;Schizophrenic · Personality Disorders · Mood Disorders
Primary: Brief Psychiatric Rating Scale (BPRS) — 29.30; 32.80; 30.25 score on a scale
Phase 3 N=400 Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection
Covid19
Primary: Number of Patients With Early Clinical Improvement — 111; 80 Participants — p=<0.03
Phase 2 N=124 Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
Coronavirus Disease 2019 (COVID-19)
Primary: The Percent of Participants With Tracheal Intubation or Death Prior to Tracheal Intubation — 26.2; 22.2 percentage of participants
Phase 4 N=1,188 The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
COVID-19 · Vaccine-Preventable Diseases · SARS CoV 2 Infection
Primary: Number of Symptomatic SARS-CoV-2 Infections Between Randomized, Study-vaccinated Participants and the Comparator Group — 48; 94 Participants
N/A N=309 Home-based Kidney Care in Native Americans of New Mexico (HBKC) - Enhancement: COVID-19 Study
CKD
Primary: Number of Participants With Problems in Their Health Care Due to COVID-19 Related Isolation — 155 Participants
Phase 2 N=98 COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients
COVID-19 · SARS-CoV 2
Primary: Percent of Healthcare Workers Testing Positive for COVID-19. — 0; 0 percentage of healthcare workers
N/A N=15 Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)
Coronavirus
Primary: Deterioration Resulting in Healthcare Review — 10 alerts generated
Phase 2 N=256 Study of AZD1222 for the Prevention of COVID-19 in Japan
COVID-19
Primary: Percentage of Participants With Seroresponse to the Spike (S) Antigen of AZD1222 as Measured by Meso Scale Discovery (MSD) Serology Assay — 100.0; 0.0; 100.0; 0.0…
N/A N=330 Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19
COVID-19
Primary: Number of Subjects With Sustained Resolution of COVID-19 Signs and Symptoms Without Subsequent Symptom Recurrence or Disease Progression (Until the End of the Study)…
N/A N=214 Symptom-Based Markers for COVID-19 Transmission
Covid19
Primary: Body Temperature — 98.1 degrees Fahrenheit
N/A N=20 CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))
Diabetes Mellitus · Covid19
Primary: Mean Absolute Relative Difference (MARD) — 10.1 percentage of MARD
Phase 2 N=25 Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19
Covid19 · Pneumonia, Viral
Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…
N/A N=172 Addressing COVID-19 Mental Health Problems Among US Veterans
Brief Video-based Intervention · Vignette Based Intervention · Non Intervention Control Arm
Primary: Help Seeking Intention — 7.4; 7.9; 7.3; 8.2 units on a scale — p=0.031
Phase 3 N=49 Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
COVID-19
Primary: Number of Subjects Experiencing TEAEs — 16; 12; 9; 2 Participants
N/A N=216 Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19
COVID19
Primary: Time to Sustained Resolution of COVID-19 Signs and Symptoms in All Subjects (With Mild or Moderate Disease at Baseline). — 113.5; 172.1; 115.1; 63.8 Time in hours…